Log in

NASDAQ:MRNAModerna Stock Price, Forecast & News

$74.10
+0.34 (+0.46 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$73.01
Now: $74.10
$75.39
50-Day Range
$58.57
MA: $70.79
$94.85
52-Week Range
$12.30
Now: $74.10
$95.21
Volume8.75 million shs
Average Volume34.88 million shs
Market Capitalization$27.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.69
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNA
CUSIPN/A
CIKN/A
Phone617-714-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.21 million
Book Value$3.49 per share

Profitability

Net Income$-514,020,000.00
Net Margins-461.42%

Miscellaneous

Employees760
Market Cap$27.51 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$74.10
+0.34 (+0.46 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Moderna (NASDAQ:MRNA) Frequently Asked Questions

How has Moderna's stock been impacted by COVID-19 (Coronavirus)?

Moderna's stock was trading at $23.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRNA shares have increased by 213.9% and is now trading at $74.10.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Moderna?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Moderna
.

When is Moderna's next earnings date?

Moderna is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Moderna
.

How were Moderna's earnings last quarter?

Moderna Inc (NASDAQ:MRNA) issued its earnings results on Wednesday, August, 5th. The company reported ($0.31) EPS for the quarter, beating the Zacks' consensus estimate of ($0.36) by $0.05. The company earned $66.35 million during the quarter, compared to analysts' expectations of $24.24 million. Moderna had a negative return on equity of 36.02% and a negative net margin of 461.42%. The business's quarterly revenue was up 407.2% on a year-over-year basis.
View Moderna's earnings history
.

What price target have analysts set for MRNA?

17 Wall Street analysts have issued 1 year price objectives for Moderna's stock. Their forecasts range from $24.00 to $134.00. On average, they anticipate Moderna's share price to reach $88.65 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price.
View analysts' price targets for Moderna
.

Has Moderna been receiving favorable news coverage?

News stories about MRNA stock have been trending very positive on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Moderna earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Moderna
.

Are investors shorting Moderna?

Moderna saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 24,710,000 shares, a decline of 13.7% from the July 15th total of 28,640,000 shares. Based on an average daily trading volume, of 25,770,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 8.0% of the shares of the stock are sold short.
View Moderna's Short Interest
.

Who are some of Moderna's key competitors?

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Walt Disney (DIS), Paypal (PYPL), Tesla (TSLA) and Micron Technology (MU).

Who are Moderna's key executives?

Moderna's management team includes the following people:
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder, Chairman & Member of Technology Advisory Board (Age 56)
  • Mr. Stéphane Bancel, CEO & Director (Age 46)
  • Dr. Stephen Hoge, Pres (Age 43)
  • Dr. Lorence H. Kim, Chief Financial Officer (Age 45)
  • Jennifer Lee, Chief Accounting Officer

When did Moderna IPO?

(MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

What is Moderna's stock symbol?

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

Who are Moderna's major shareholders?

Moderna's stock is owned by many different institutional and retail investors. Top institutional investors include Ropes Wealth Advisors LLC (0.48%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Swiss National Bank (0.28%), Frontier Capital Management Co. LLC (0.15%), New York State Common Retirement Fund (0.12%) and First Trust Advisors LP (0.11%). Company insiders that own Moderna stock include Edwin M Kania Jr, Elizabeth G Nabel, Jennifer Ling Lee, Juan Andres, Lorence H Kim, Lori M Henderson, Paul Sagan, Peter Barton Hutt, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and Ventures Fund Iv Gene Flagship.
View institutional ownership trends for Moderna
.

Which major investors are selling Moderna stock?

MRNA stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Ropes Wealth Advisors LLC, Cambridge Investment Research Advisors Inc., First Trust Advisors LP, Ariose Capital Management Ltd, Hellman Jordan Management Co. Inc. MA, DekaBank Deutsche Girozentrale, and Moloney Securities Asset Management LLC. Company insiders that have sold Moderna company stock in the last year include Edwin M Kania Jr, Elizabeth G Nabel, Jennifer Ling Lee, Juan Andres, Lorence H Kim, Lori M Henderson, Peter Barton Hutt, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Moderna
.

Which major investors are buying Moderna stock?

MRNA stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Swiss National Bank, Candriam Luxembourg S.C.A., Oregon Public Employees Retirement Fund, Robeco Institutional Asset Management B.V., Elephas Investment Management Ltd, State Board of Administration of Florida Retirement System, and Raymond James & Associates.
View insider buying and selling activity for Moderna
.

How do I buy shares of Moderna?

Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Moderna's stock price today?

One share of MRNA stock can currently be purchased for approximately $74.10.

How big of a company is Moderna?

Moderna has a market capitalization of $27.51 billion and generates $60.21 million in revenue each year. The company earns $-514,020,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Moderna employs 760 workers across the globe.

What is Moderna's official website?

The official website for Moderna is www.modernatx.com.

How can I contact Moderna?

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-6500 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.